Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis

• Published in: eNeurologicalSci Vol. 31; p. 100468
• Main Authors: Zaki, Hany A., Iftikhar, Haris, Najam, Mavia, Masood, Maarij, Al-Marri, Nood Dhafi R., Elgassim, Mohamed Abdelgadir M., Fayed, Mohamed, Shaban, Eman E.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-06-2023; Elsevier
• Subjects: Guillain-Barre syndrome; Immunoglobulins; Intravenous; Plasma exchange; Review; Systematic; Plasma exchange; Immunoglobulins; Review; Guillain-Barre syndrome; Intravenous; Systematic
• ISSN: 2405-6502; 2405-6502
• DOI: 10.1016/j.ensci.2023.100468

Guillain- Barré syndrome (GBS) is a neuropathic condition that leads to the rapid development of impairments and is characterized by weakness and numbness or tingling sensation in the legs and arms and sometimes loss of movement and feeling in the legs, arms, upper body, and face. Currently, the cure for the disease is yet to be developed. However, treatment options such as intravenous immunoglobulin (IVIG) and plasma exchange (PE) have been used to minimize the symptoms and duration of the disease. Therefore, this systematic review and meta-analysis compared the efficacy of IVIG and PE in treating GBS patients with severe symptoms.
Six electronic databases, including PubMed, Embase, Scopus, ScienceDirect, Medline, and Google scholar, were scoured for articles related and relevant to our research. Additionally, more studies were obtained through the reference lists of the studies retrieved from these electronic databases. Quality assessment and statistical data analysis were conducted using Review Manager software (RevMan 5.4.1).
The search for relevant articles resulted in 3253 articles, of which only 20 were included for review in the current study. A sub-group analysis indicated no significant difference in the curative effect (Hughes score reduces by at least one score 4 weeks after GBS treatment; OR: 1.00; 95% CI: 0.66–1.52; p = 1.00 and Achieving grade 0 or 1 on Hughes scale; OR: 1.03; 95% CI: 0.27–3.94; p = 0.97). Similarly, the statistical showed that the difference in length of hospitalization and duration of mechanical ventilation was insignificant between the IVIG and PE group (Standard Mean Difference (SMD): -0.45; 95% CI: −0.92, 0.02; I2 = 91%; p = 0.06 and SMD: -0.54; 95% CI: −1.67, 0.59; I2 = 93%; p = 0.35, respectively). Moreover, the meta-analysis did not find any significant difference in the risk of GBS relapse (RR: 0.47; 95% CI: 0.20–1.14; p = 0.10) and risk of complications related to the treatment regimens (RR: 1.03; 95% CI: 0.71–1.48; p = 0.89). However, the statistical analysis of outcomes from 3 studies showed that the risk of discontinuation was significantly lower in the IVIG group than in the PE group (RR: 0.22; 95% CI: 0.06–0.88; p = 0.03).
Our study suggests that IVIG and PE have similar curative effects. Similarly, IVIG seems easier to use and thus can be preferred for treating GBS.
•Intravenous immunoglobulin (IVIG) and plasma exchange (PE) provide similar curative effects and relapse rates.•The reductions in hospitalization and ventilation length, and the potential risk of complications are also similar.•IVIG is easier to use and might be preferred for treating patients with severe symptoms of Guillain-Barré syndrome (GBS).•Offering both treatments for patients with GBS does not influence the curative effect.•The risk of being discontinued from IVIG treatment was significantly lower than PE treatment.